Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Vanqua Bio | 2024 | Venture - Series Unknown | $45.0M | Chicago |
| Radar Therapeutics | 2024 | Seed | $13.4M | Berkeley |
| Firefly Bio | 2024 | Series A | $94.0M | San Francisco |
| Prism BioLab | 2024 | Series C | $10.2M | Fujisawa |
| GenEdit | 2024 | Series A | $24.0M | South San Francisco |
| Mariana Oncology | 2023 | Series B | $175.0M | Watertown |
| Nido Biosciences | 2023 | Series B | $86.6M | Watertown |
| DiogenX | 2023 | Series A | $36.8M | Marseille |
| Sanegene Bio | 2025 | Series B | $110.0M | Woburn |
| Juvena Therapeutics | 2026 | Series B | $33.5M | Palo Alto |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Vanqua Bio | Venture - Series Unknown | $45.0M | Chicago, United States |
| 27 | Radar Therapeutics | Seed | $13.4M | Berkeley, United States |
| 28 | Firefly Bio | Series A | $94.0M | San Francisco, United States |
| 29 | Prism BioLab | Series C | $10.2M | Fujisawa, Japan |
| 30 | GenEdit | Series A | $24.0M | South San Francisco, United States |
| 31 | Mariana Oncology | Series B | $175.0M | Watertown, United States |
| 32 | Nido Biosciences | Series B | $86.6M | Watertown, United States |
| 33 | DiogenX | Series A | $36.8M | Marseille, France |
| 34 | Sanegene Bio | Series B | $110.0M | Woburn, United States |
| 35 | Juvena Therapeutics | Series B | $33.5M | Palo Alto, United States |
Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.
Radar Therapeutics pioneer in treatment modality, precision-expressed mRNA-based therapeutics.
Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Prism is a biotechnology company that develops therapeutic drugs that cure intractable diseases using unique peptide mimic technology.
GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.
Mariana Oncology is a biotechnology research industry.
Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.
DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.
Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.
Juvena Therapeutics develops tissue-restorative biologics to address chronic muscle and age-related conditions.
Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
BreezeBio is a biotechnology business that creates genetic therapies using precision, non-viral delivery across clinically important tissues
TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.
Recludix pharma is a developing platform to treat cancer patients.
ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.
InduPro deevlops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease.
Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.
ABL Bio is a biotech research company that focuses on the development of therapeutic drugs for immuno-oncology diseases.
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Crossbow Therapeutics is a biotech company developing a new type of cancer treatment.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Eli Lilly has invested in 110 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Eli Lilly's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 16 different industry categories.
Among tracked funding rounds, Mariana Oncology received $175.0M in a Series B round. Eli Lilly's total known invested capital is $4.1B.
Eli Lilly's average investment size is $49.3M across its portfolio of 110 companies.
Recent Eli Lilly portfolio additions include Vanqua Bio, Radar Therapeutics, Firefly Bio, Prism BioLab, GenEdit. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors